- 著者
- 結核療法研究協議会
- 出版者
- 一般社団法人 日本結核病学会
- 雑誌
- 結核 (ISSN:00229776)
- 巻号頁・発行日
- vol.49, no.7, pp.207-215, 1974
The efficacy and the side-effects of Tuberactinomycin-N (TUM-N) in the retreatment of pulmonary tuberculosis were studied and compaired with those of Viomycin (VM). The drug resistance of tubercle bacilli isolated from the patients during treatment was also studied for TUM-N and VM.<BR>TUM-N i s a new antituberculous drug isolated from the culture filtrate of Streptomyces. griseoverticillatus var. tuberacticus (N 6-130 strain). This drug shows almost the same activity as VM for tubercle bacilli and one way cross resistance for kanamycin.<BR>In this study, two following regimens were allocated ran d o mly for retreated patients.<BR>(1) TUM-N group: TUM-N was injected 1 g daily for the first three months, thereafter injected twice weekly. (45 cases)<BR>(2) VM group: VM wa s injected 1 g three times a week. (38 cases)<BR>If there are previously unused drug, they were combined with TUM-N or VM. The results were summarized as follows;<BR>(1) TUM-N group showed slmo s t the same negative conversion rate on culture as VM, group.<BR>(2) All of the cases treated with TUM-N combined with two previously unused drugs. showed 100% negative conversion rate on culture at 6 months.<BR>(3) The incidence of side-effects was lower in TU M -N group compared with VM group. The auditory disturbance was 2.2% in TUM-N group and 5.7% in VM group. The renal, disturhance defined by the raise of BUN level over 20 mg/d<I>l</I> was observed in 23.7% among -VM group while it was 10.9% in TUM-N group. The dropped-out cases due to side-effects -were 3 (6.5%) among 46 cases of TUM-N group and 8(21.2%) among 38 cases of VM group.<BR>(4) The criterion of drug resistance of TUM-N was examined and it was concluded that the growth on 1% Ogawa's media containing 100 mcg/m<I>l</I> TUM-N should be considered as resistant.
- 著者
- 結核療法研究協議会
- 出版者
- 一般社団法人 日本結核病学会
- 雑誌
- 結核 (ISSN:00229776)
- 巻号頁・発行日
- vol.46, no.8, pp.325-333, 1971 (Released:2011-05-24)
- 参考文献数
- 6
Tuberculosis Research Committee (Ryoken) investigated comparatively the therapeutic effects of three regimens, i. e., standard triple treatment with SM⋅INH⋅PAS (EB0 group), standard triple treatment plus EB twice weekly (EB2 group) and standard triple treatment plus EB daily (EB7 group), in order to intensify the initial treatment for pulmonary tuberculosis.The cases with positive tubercle bacilli and cavities were subjected to this study and were allocated at random for three regimens.The total number of the c a ses was 272 at the beginning of the treatment, but 48 cases were excluded from the analysis because of the primary drug resistance, etc. Finally, 74cases of EB0 group, 74 cases of EB2 group and 76 cases of EB7 group were analyzed.SM was injected 1 g a day twice weekly, INH was given O.4 g daily in two divided doses, PAS was administered 10 g daily in three divided doses, and EB was given 750 mg daily or twice weekly at the same day when SM was injected.The background factors of the cases in ea c h group were almost similar, but the cases with abundant bacilli on smear and (_??_) by culture were observed somewhat less frequently in EB2 group than in the other two groups.As to the rates of the radiological improvement and the sputum conversion rate, there was no significant difference among three groups. However, the moderate improvement of the fibrocaseous lesions and cavities were recognized sooner in EB2 and EB7 groups than in EB0 group.The number of cases, in which the regimens were changed because of side effects or ineffectiveness, were 8 cases in EB0, group, 9 cases in EB2 group and 5 cases in EB7 group. The number of cases with positive sputum by smear or culture after 12 month's treatments were 3 in EB0 group, none in EB2 group and 1 in EB7 group. Therefore, the rate of these unsuccesful cases in EB0, group, EB2 group and EB7 group was 16.7%, 13.6% and 8.3%, respectively.In order to prove the difference in the effectiveness among three regimens, the follow up-studies for longer period might be required.